If the cost of administering the PBS evaluation and listing process is rising at such a high rate, which apparently it is, it might be worth questioning its performance, including the potential to implement efficiencies to reduce the cost and make it faster. …
If the cost of this process is truly rising at this rate, then the process must be the problem
August 12, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
OncoSil completes first production run at new Sydney manufacturing facility
December 17, 2025 - - Australian Biotech -
Island Pharmaceuticals secures key partnership with Texas Biomed
December 17, 2025 - - Australian Biotech -
Novartis names new Country President following leadership transition
December 16, 2025 - - Latest News -
Mayne Pharma opens expanded manufacturing facility after termination of takeover
December 16, 2025 - - Latest News -
Budget update includes impact of listings, but generally not much else
December 16, 2025 - - Latest News -
The UK reconfirms the direct impact of the transatlantic shift in medicine pricing
December 16, 2025 - - Latest News -
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News